Additional eculizumab dose and tacrolimus discontinuation for treatment of COVID-19 in a kidney transplant recipient with aHUS
- PMID: 34272820
- PMCID: PMC8420508
- DOI: 10.1111/1744-9987.13710
Additional eculizumab dose and tacrolimus discontinuation for treatment of COVID-19 in a kidney transplant recipient with aHUS
Conflict of interest statement
The authors have declare no conflict of interest.
Comment on
-
Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome.Clin Kidney J. 2020 Sep 27;13(5):739-741. doi: 10.1093/ckj/sfaa166. eCollection 2020 Oct. Clin Kidney J. 2020. PMID: 33117528 Free PMC article.
References
-
- Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, et al. Atypical hemolytic‐uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23:4–21. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical